Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

TREATMENT OF RAPID CYCLING BIPOLAR ILLNESS 29TH ANNUAL MEETING OF THE NEW CLINICAL DRUG EVALUATION UNIT Post, R. M., Kramlinger, K. G., Altshuler, L. L., Ketter, T., Denicoff, K. US GOVERNMENT PRINTING OFFICE. 1990: 37–47

Abstract

Rapid cycling patients (greater than or equal to 4 episodes/year) often show inadequate response to lithium carbonate and are vulnerable to antidepressant-induced switches or cycle acceleration. Treatment with the anticonvulsant carbamazepine is now an accepted adjunct or alternative, and a series of uncontrolled studies also suggest the utility of valproate in this patient population. Clonazepam, suppressive doses of thyroid, calcium channel blockers, and other innovative treatments appear promising and deserve careful clinical investigation.

View details for Web of Science ID A1990DL70200007

View details for PubMedID 2196625